Trulicity vs Ozempic vs Mounjaro for T2D: Head-to-Head Evidence

Three once-weekly injections sit at the top of the modern type 2 diabetes ladder. Trulicity (dulaglutide, Lilly, FDA-approved 2014) was the first to make once-weekly dosing dominant. Ozempic (semaglutide, Novo Nordisk, FDA-approved 2017) raised the A1c and weight-loss ceiling and added a cardiovascular outcomes indication. Mounjaro (tirzepatide, Lilly, FDA-approved 2022) added a second incretin axis — GIP agonism on top of GLP-1 — and is currently the most potent of the three on A1c and weight. Only one direct head-to-head of any pair has been published (SURPASS-2, tirzepatide vs semaglutide 1 mg^[2]). The rest of the comparisons come from same-trial benchmarks (SUSTAIN-7, semaglutide vs dulaglutide^[1]) and anchored indirect comparisons across SURPASS, AWARD, and SUSTAIN programs. This article walks through the trial evidence, the cardiovascular data, the practical prescribing differences, and the patient-level decision framework.

The honest summary

• On A1c at maximum dose, Mounjaro 15 mg produces the largest reduction (about −2.4% from a baseline near 8.5% in SURPASS-2^[2]), Ozempic 2 mg and Trulicity 4.5 mg are close to each other (about −1.8% to −2.1%), and the lower doses of each drug drop A1c by roughly 1.0–1.5%.
• On weight, the spread is wider. SURPASS-2 reported −11.2 kg on tirzepatide 15 mg vs −5.7 kg on semaglutide 1 mg^[2]. AWARD-11 reported −4.6 kg on dulaglutide 4.5 mg^[3]. Mounjaro is the clear leader; Ozempic and Trulicity are closer to each other.
• On cardiovascular outcomes, Trulicity has the broadest population evidence (REWIND, Gerstein 2019 Lancet^[5]: 12% relative MACE reduction across a mostly-primary-prevention cohort). Ozempic showed a 26% relative MACE reduction in the secondary-prevention SUSTAIN-6 trial^[6]. Mounjaro’s dedicated CV outcomes trial (SURPASS-CVOT, head-to-head against dulaglutide) is ongoing.
• On practical prescribing, Trulicity has the simplest device (single-use pre-filled autoinjector, no dialing). Ozempic uses a multi-use dial pen. Mounjaro ships as single-use prefilled pens. All three have similar retail cash prices in the United States (roughly $900–$1,100 per month) and all three sit behind prior authorization on most commercial plans.

SUSTAIN-7: the only large head-to-head of semaglutide vs dulaglutide

SUSTAIN-7 (Pratley 2018, Lancet Diabetes & Endocrinology^[1]) randomized 1,201 adults with type 2 diabetes on background metformin to one of four arms: semaglutide 0.5 mg vs dulaglutide 0.75 mg, or semaglutide 1.0 mg vs dulaglutide 1.5 mg. At 40 weeks the higher-dose comparison showed:

• A1c reduction: −1.8% on semaglutide 1.0 mg vs −1.4% on dulaglutide 1.5 mg (estimated treatment difference roughly −0.4%, statistically significant in favor of semaglutide).
• Body weight: −6.5 kg on semaglutide 1.0 mg vs −3.0 kg on dulaglutide 1.5 mg — a clinically meaningful gap of about 3.5 kg.
• A1c target attainment (<7%): 79% on semaglutide 1.0 mg vs 67% on dulaglutide 1.5 mg.
• Adverse events: gastrointestinal events were broadly similar between the two drugs, with nausea rates in the mid-teens for both. Discontinuation rates were similar.

The trial was open-label by necessity (different devices) but the primary efficacy endpoints used blinded laboratory measurement. SUSTAIN-7 remains the cleanest available direct comparison and the basis for the prescribing intuition that Ozempic generally outperforms Trulicity head-to-head at matched intent doses, with a similar tolerability profile. AWARD-11 (Frias 2021^[3]) later added the 3.0 mg and 4.5 mg dulaglutide arms above the SUSTAIN-7 ceiling and partially closed the gap.

AWARD-11: extending Trulicity to 3.0 and 4.5 mg

AWARD-11 (Frias 2021, Diabetes Care^[3]) randomized 1,842 adults on metformin to dulaglutide 1.5 mg, 3.0 mg, or 4.5 mg weekly. At 36 weeks:

• A1c (mean baseline 8.6%): −1.54% on 1.5 mg, −1.71% on 3.0 mg, and −1.87% on 4.5 mg (significant additional benefit at each step).
• Body weight: −3.0 kg on 1.5 mg, −4.0 kg on 3.0 mg, −4.6 kg on 4.5 mg.
• GI adverse events: nausea 13.4% on 1.5 mg, 15.6% on 3.0 mg, 16.4% on 4.5 mg — small dose-related increase but no large jump.

Trulicity 4.5 mg therefore lands roughly where Ozempic 1.0 mg sits in SUSTAIN-7 on A1c (about −1.8% to −1.9%) but lags on weight loss. AWARD-2 (Giorgino 2015^[4]) previously established dulaglutide’s comparison against insulin glargine: dulaglutide 1.5 mg dropped A1c more than glargine titrated to fasting glucose target, with weight loss of 1.9 kg vs weight gain of 1.4 kg on glargine.

SURPASS-2: the only direct head-to-head of tirzepatide vs semaglutide

SURPASS-2 (Frias 2021, NEJM^[2]) randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10, or 15 mg weekly or semaglutide 1.0 mg weekly. At 40 weeks:

• A1c (mean baseline 8.3%): −2.01% on tirzepatide 5 mg, −2.24% on 10 mg, −2.30% on 15 mg, vs −1.86% on semaglutide 1.0 mg.
• Body weight: −7.6 kg on tirzepatide 5 mg, −9.3 kg on 10 mg, −11.2 kg on 15 mg, vs −5.7 kg on semaglutide 1.0 mg.
• A1c <5.7% (non-diabetic range) was reached by 27% of tirzepatide 5 mg, 40% of 10 mg, and 46% of 15 mg patients vs 19% on semaglutide 1.0 mg.
• Nausea: 17–22% across tirzepatide arms vs 18% on semaglutide. Discontinuation for adverse events was similar (about 5–7%).

The SURPASS-2 comparator was semaglutide 1.0 mg, not 2.0 mg. Ozempic 2.0 mg (approved in 2022 based on SUSTAIN FORTE) adds roughly an extra 0.2–0.3% A1c reduction and a small additional weight benefit beyond 1.0 mg. That partially narrows the gap to tirzepatide but does not close it: at maximum approved doses, Mounjaro still outperforms Ozempic on both A1c (about −2.4% vs −2.1%) and weight (about −12 kg vs −7 kg in T2D populations).

Cardiovascular outcomes: REWIND, SUSTAIN-6, LEADER, and SURPASS-CVOT pending

REWIND (Gerstein 2019, Lancet^[5]) randomized 9,901 adults with type 2 diabetes to dulaglutide 1.5 mg or placebo and followed them for a median of 5.4 years. Only 31% had prior established cardiovascular disease at entry, making REWIND the largest primary-prevention-skewed GLP-1 CV outcomes trial. The primary three-point MACE outcome (CV death, non-fatal myocardial infarction, non-fatal stroke) was reduced by 12% (HR 0.88, 95% CI 0.79–0.99, p=0.026). The effect was consistent across the primary and secondary prevention subgroups. The FDA approved Trulicity for MACE reduction in adults with type 2 diabetes who have established CVD or multiple CV risk factors on the basis of REWIND.

SUSTAIN-6 (Marso 2016, NEJM^[6]) randomized 3,297 adults with type 2 diabetes and high CV risk to semaglutide (0.5 or 1.0 mg) or placebo for a median 2.1 years. Three-point MACE was reduced by 26% (HR 0.74, 95% CI 0.58–0.95, p=0.02 for superiority). Non-fatal stroke drove much of the benefit; cardiovascular death and non-fatal MI showed numerically but not significantly fewer events. SUSTAIN-6 was a pre-marketing safety trial rather than a powered superiority trial, but the result was strong enough to inform Ozempic’s label and the AHA/ADA preference ordering.

LEADER (Marso 2016, NEJM^[7]) randomized 9,340 adults with type 2 diabetes and high CV risk to liraglutide or placebo for a median 3.8 years. Three-point MACE was reduced by 13% (HR 0.87, 95% CI 0.78–0.97, p=0.01). LEADER established the class-effect prior on which SUSTAIN-6 and REWIND built; it is the cardiovascular backbone for daily semaglutide’s sibling, liraglutide (Victoza/Saxenda).

SURPASS-CVOT is the dedicated tirzepatide vs dulaglutide head-to-head CV outcomes trial run by Lilly. It randomized about 13,000 adults with type 2 diabetes and established atherosclerotic CVD; topline results are expected in 2026–2027. Until those results are public, Mounjaro does not have a dedicated MACE-reduction indication, although the SURPASS program showed no CV safety signal. The intermediate path for cardiology-driven prescribing today is Ozempic (SUSTAIN-6) or Trulicity (REWIND).

Renal outcomes

REWIND, SUSTAIN-6, and LEADER all showed signal toward reduced renal composite outcomes (new macroalbuminuria, sustained eGFR decline, end-stage renal disease, or renal death). For semaglutide, the FLOW trial (Perkovic 2024, NEJM) later confirmed a primary-prevention-of-renal-progression benefit in dedicated CKD populations. Tirzepatide does not yet have a published renal outcomes trial; SURPASS-CVOT includes renal endpoints as secondary outcomes.

Side-effect profiles in practice

The three drugs share the GLP-1 class’s gastrointestinal signature: nausea, diarrhea, constipation, vomiting. The 12-month nausea rate is approximately 14% for dulaglutide (AWARD-11^[3]), 16% for semaglutide (SUSTAIN-7^[1]), and 16–22% for tirzepatide (SURPASS-2^[2]). Dulaglutide is sometimes reported to have the gentlest titration because it has effectively no titration — patients start at 0.75 mg and stay there or step up to 1.5 mg at 4 weeks. Tirzepatide has the longest ladder (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) and the longest exposure to titration-window GI side effects.

Class-level boxed warnings (medullary thyroid carcinoma risk, contraindicated in MEN-2 syndrome) apply to all three. Pancreatitis precautions, gallbladder disease, and diabetic retinopathy progression caveats apply to all three. Mounjaro does not share semaglutide’s and dulaglutide’s track record at the post-marketing time horizon — it has been on the market less than four years — but pharmacovigilance signals have been broadly consistent with class expectations.

Devices, dosing, and the practical patient decision

• Trulicity ships as single-use pre-filled autoinjector pens at 0.75, 1.5, 3.0, and 4.5 mg. No dial. No needle handling. Patients press the pen against the skin and click. This is the simplest device of the three.
• Ozempic ships as multi-use pens that deliver 0.25, 0.5, 1.0, or 2.0 mg per click depending on the pen variant. Patients change needles each dose and dial the dose. More steps than Trulicity but a single pen covers several weeks.
• Mounjaro ships as single-use prefilled pens at each dose strength (2.5, 5, 7.5, 10, 12.5, 15 mg) and as single-use vials for cash-pay patients via LillyDirect. Each weekly injection is one disposable pen.

Patient-level decision heuristics that prescribers commonly use:

• New T2D diagnosis, obesity is the dominant comorbidity: Mounjaro first-line. The weight-loss magnitude is the largest of the three and translates into insulin-sensitivity gains that pull A1c down even before maximum titration.
• New T2D diagnosis, established atherosclerotic CVD: Ozempic 2 mg or Mounjaro. SUSTAIN-6 supports Ozempic’s MACE-reduction claim; Mounjaro’s CV safety profile in SURPASS was clean and SURPASS-CVOT will read out shortly.
• New T2D, primary prevention only, broad MACE risk: Trulicity. REWIND’s primary-prevention-skewed population is the closest match.
• Established on Trulicity at A1c target: continue. The cheaper-and-simpler device wins when glycemic control is already adequate.
• Established on Trulicity 4.5 mg but A1c not at target: switch to Ozempic 1 or 2 mg or to Mounjaro. No washout is required; the next scheduled weekly dose becomes the starter dose of the new drug per label^[8][9].
• Pregnancy planning within 2 months: none of the three. All three require a 2-month washout before conception per label.

Insurance and cost in the United States

Retail cash prices are similar (approximately $900–$1,100 per month for all three at maximum dose). Insurance coverage is the operative variable. Trulicity has been on commercial formularies for over a decade and tends to face less restrictive prior authorization for type 2 diabetes (an A1c above target and a metformin trial are usually sufficient). Ozempic and Mounjaro increasingly require explicit documentation of metformin and often a sulfonylurea or another GLP-1 trial, particularly when the off-label weight-loss demand has tightened plan criteria.

For cash-pay patients, Mounjaro single-dose vials via LillyDirect Self Pay (at the cap-set price of around $499/month for the lower doses and up to $649 for the higher doses as of 2026) and Wegovy vials via NovoCare are the two manufacturer cash pathways. There is no equivalent Trulicity cash program at a comparable discount; cash prescriptions for Trulicity continue to track retail.

Related research

• Mounjaro vs Trulicity: glycemic control and switching — the same-manufacturer head-to-head deep dive
• Mounjaro vs Zepbound switching — same molecule (tirzepatide), different label and insurance status
• Tirzepatide vs semaglutide head-to-head — the SURPASS-2 trial in detail and what it implies for obesity prescribing
• GLP-1 prior authorization appeal strategy — how to get past step-therapy when one of the three is preferred by the plan

Important disclaimer. This article is educational and does not constitute medical advice. Choice among Trulicity, Ozempic, and Mounjaro should be made with a prescribing clinician based on the individual’s cardiovascular history, renal function, weight goals, prior treatments, insurance coverage, and tolerance for gastrointestinal side effects. Class boxed warnings for medullary thyroid carcinoma apply to all three. Pregnancy and lactation are contraindications. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: at SURPASS-CVOT topline readout (expected 2026–2027) or 12 months, whichever is sooner.